RTW Investments, LP and its Managing Partner Roderick Wong, M.D. filed Amendment No. 4 to their beneficial ownership statement covering Tenax Therapeutics, Inc. common stock, disclosing a position of zero shares as of September 30, 2026, with the filing submitted on November 16, 2026.

Key Highlights

  • Zero beneficial ownership: Both RTW Investments, LP and Roderick Wong, M.D. each report 0.00 shares beneficially owned in Tenax Therapeutics, Inc. common stock.
  • 0.0% of class: The percent of class represented by the aggregate amount beneficially owned is reported as 0.0% for each reporting person.
  • Event date: The date of the event requiring this filing is stated as September 30, 2026.
  • Amendment number: This filing is Amendment No. 4 to the reporting persons' prior statement on Tenax Therapeutics common stock (CUSIP 88032L605).
  • Reporting persons: RTW Investments, LP is classified as an investment adviser and limited partnership; Roderick Wong, M.D. is identified as Managing Partner and Chief Investment Officer of RTW Investments, filing as an individual.
  • RTW Funds: According to the filing, the RTW Funds retain the right to receive dividends from, or proceeds from the sale of, the shares reported, though the aggregate reported is zero.

RTW Investments and Roderick Wong Report Full Exit from Tenax Therapeutics Position

RTW Investments, LP, a Delaware limited partnership that serves as investment adviser to a group of funds referred to in the filing as the "RTW Funds," and Roderick Wong, M.D., the Managing Partner and Chief Investment Officer of RTW Investments, together disclosed that as of September 30, 2026, neither reporting person holds any beneficial ownership in the common stock of Tenax Therapeutics, Inc. The filing reports sole voting power, shared voting power, sole dispositive power, and shared dispositive power each at 0.00 for both parties, with an aggregate beneficial ownership of 0.00 shares representing 0.0% of the class.

Tenax Therapeutics, Inc. is a biopharmaceutical company headquartered at 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517, according to the filing. The common stock subject to this disclosure carries a par value of $0.0001 per share and is identified by CUSIP number 88032L605. The filing is listed on NASDAQ:TENX. The reporting persons' business address is listed as 40 10th Avenue, Floor 7, New York, New York 10014. RTW Investments, LP and Dr. Wong first entered into a joint filing agreement incorporated by reference to an exhibit originally filed with the SEC on May 15, 2025.

The filing states that it "should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein." Item 5 of the filing designates ownership as "5 percent or less of a class." The certification included in the filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

RTW Investments, LP and Roderick Wong, M.D. filed Amendment No. 4 to their ownership statement for Tenax Therapeutics, Inc. common stock, reporting zero shares beneficially owned and 0.0% of the class as of September 30, 2026, with the statement signed and dated November 16, 2026.